The stock price of Avidity Biosciences Inc (NASDAQ: RNA) has jumped by 0.10 compared to previous close of 39.91. Despite this, the company has seen a gain of 6.22% in its stock price over the last five trading days. businesswire.com reported 2024-06-24 that SAN DIEGO–(BUSINESS WIRE)–Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (Nasdaq: RNA), as an indepen.
Is It Worth Investing in Avidity Biosciences Inc (NASDAQ: RNA) Right Now?
Additionally, the 36-month beta value for RNA is 0.90. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for RNA is 86.51M and currently, short sellers hold a 13.02% ratio of that float. The average trading volume of RNA on June 27, 2024 was 1.36M shares.
RNA’s Market Performance
RNA’s stock has seen a 6.22% increase for the week, with a 51.79% rise in the past month and a 61.94% gain in the past quarter. The volatility ratio for the week is 4.86%, and the volatility levels for the past 30 days are at 6.79% for Avidity Biosciences Inc. The simple moving average for the past 20 days is 20.55% for RNA’s stock, with a 149.27% simple moving average for the past 200 days.
Analysts’ Opinion of RNA
Many brokerage firms have already submitted their reports for RNA stocks, with BofA Securities repeating the rating for RNA by listing it as a “Buy.” The predicted price for RNA in the upcoming period, according to BofA Securities is $40 based on the research report published on May 03, 2024 of the current year 2024.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see RNA reach a price target of $60. The rating they have provided for RNA stocks is “Overweight” according to the report published on March 14th, 2024.
Evercore ISI gave a rating of “Outperform” to RNA, setting the target price at $20 in the report published on May 22nd of the previous year.
RNA Trading at 37.92% from the 50-Day Moving Average
After a stumble in the market that brought RNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -4.88% of loss for the given period.
Volatility was left at 6.79%, however, over the last 30 days, the volatility rate increased by 4.86%, as shares surge +50.77% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +67.80% upper at present.
During the last 5 trading sessions, RNA rose by +6.67%, which changed the moving average for the period of 200-days by +510.65% in comparison to the 20-day moving average, which settled at $33.81. In addition, Avidity Biosciences Inc saw 341.44% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RNA starting from LEVIN ARTHUR A, who sale 5,000 shares at the price of $37.59 back on Jun 20 ’24. After this action, LEVIN ARTHUR A now owns 14,830 shares of Avidity Biosciences Inc, valued at $187,950 using the latest closing price.
Boyce Sarah, the President and CEO of Avidity Biosciences Inc, sale 32,074 shares at $39.13 during a trade that took place back on Jun 18 ’24, which means that Boyce Sarah is holding 142,543 shares at $1,255,040 based on the most recent closing price.
Stock Fundamentals for RNA
Current profitability levels for the company are sitting at:
- -23.48 for the present operating margin
- 0.65 for the gross margin
The net margin for Avidity Biosciences Inc stands at -21.04. The total capital return value is set at -0.29. Equity return is now at value -32.91, with -29.22 for asset returns.
Based on Avidity Biosciences Inc (RNA), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -15.36. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -652.66.
Currently, EBITDA for the company is -233.5 million with net debt to EBITDA at 1.83. When we switch over and look at the enterprise to sales, we see a ratio of 310.37. The receivables turnover for the company is 6.9for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.47.
Conclusion
In conclusion, Avidity Biosciences Inc (RNA) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
